Title
Reducing the global burden of HTLV-1 infection: An agenda for research and action
Date Issued
01 January 2017
Access level
open access
Resource Type
review
Author(s)
Willems L.
Hasegawa H.
Accolla R.
Bangham C.
Bazarbachi A.
Bertazzoni U.
Carneiro-Proietti A.B.d.F.
Cheng H.
Chieco-Bianchi L.
Ciminale V.
Coelho-dos-Reis J.
Esparza J.
Gallo R.C.
Gessain A.
Hall W.
Harford J.
Hermine O.
Jacobson S.
Macchi B.
Macpherson C.
Mahieux R.
Matsuoka M.
Murphy E.
Peloponese J.M.
Simon V.
Tagaya Y.
Taylor G.P.
Watanabe T.
Yamano Y.
Tropical Medical Institute Alexander von Humboldt
Publisher(s)
Elsevier B.V.
Abstract
Even though an estimated 10–20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.
Start page
41
End page
48
Volume
137
Language
English
OCDE Knowledge area
Enfermedades infecciosas
Epidemiología
Subjects
Scopus EID
2-s2.0-85002245143
PubMed ID
Source
Antiviral Research
ISSN of the container
01663542
Sponsor(s)
We thank Natalia Mercer for manuscript preparation. This work received financial support of the “ Fonds National de la Recherche Scientifique ” (FNRS), the Télévie , the Interuniversity Attraction Poles (IAP) Program “Virus-host interplay at the early phases of infection” BELVIR initiated by the Belgian Science Policy Office , the Belgian Foundation against Cancer (FBC), the “ Centre anticancéreux près ULg ” (CAC) and the “ Fonds Léon Fredericq ” (FLF), the “AgricultureIsLife” project of Gembloux Agrobiotech (GxABT) , the “ ULg Fonds Spéciaux pour la Recherche ” and the “Plan Cancer” of the “ Service Public Fédéral ”.
Sources of information:
Directorio de Producción Científica
Scopus